London, United Kingdom, June 27, 2016 --(PR.com
)-- SMi Group’s 5th annual conference on Orphan Drugs and Rare Diseases returns to London this Autumn and will explore how payers, pharmaceutical, biotech and patient organisations are preparing to participate in and leverage the growing orphan drugs and rare diseases industry. A detailed agenda is available on www.orphandrugs-event.com/prcom.
Joining the expert lineup for the CPD-certified event, taking place in London on the 19th and 20th of October, are top decision makers from MHRA, Chiesi and Findacure.
Daniel O’Connor, Medical Assessor at MHRA, joins a panel discussion of partnerships improving the orphan drug field. Daniel, along with other specialists, will explore how to make multi-stakeholder partnerships successful, what role each stakeholder plays, and how collaboration and partnership can improve the orphan drugs access to market.
Diego Ardigo, Project Leader at Chiesi, will present on the rise of one-off gene and cell therapy treatments for rare diseases. His talk will highlight development considerations in demonstrating long-term efficacy for advanced therapies in the orphan drug space as well as critical issues in the generation and evaluation of value for advanced therapies.
Findacure Scientific Officer Richard Thompson will explore strategies in developing a new model to fund drug repurposing for rare diseases. Richard’s presentation will highlight the benefits of drug repurposing, the use of a social impact bond to fund rare disease drug repurposing while saving the NHS money, and the assessment of the current costs of rare diseases to validate the social impact bond model.
The speaker lineup also includes key experts from Abeona Therapeutics, NICE, Alexion Pharma, Mereo BioPharma, Cell Medica, Cydan Development, Tikomed, and much more. A full list of speakers and their topics can be viewed at http://www.orphandrugs-event.com/prcom
The conference also offers two interactive half-day pre-conference workshops:
- Planning for success: Developing the optimal orphan drug development strategy hosted by Cell Medica and Chiesi Farmaceutici
- Paving the way for achieving orphan drug market access hosted by RJW & Partners
For those interested in attending Orphan Drugs 2016, registration is live online at http://www.orphandrugs-event.com/prcom. For those interested to speak or to exhibit at the event, please contact Alia Malick on +44(0)207 827 6168 or firstname.lastname@example.org.
For media enquiries please contact Honey de Gracia on +44(0)207 827 6102 or email@example.com.
5th Orphan Drugs Conference and Exhibition
19-20 October 2016, London, UK
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk.